Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naxitamab Chemoimmunotherapy for High-Risk Neuroblastoma (Study 203)
NCT04560166Phase 2Terminated
- Sponsor
- Y-mAbs Therapeutics, Inc.
- Start
- Nov 2021
- Primary completion
- Sep 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of naxitamab in neuroblastoma, sponsored by Y-mAbs Therapeutics, Inc. Primary endpoint: Overall Response Rate at 84 days. Started Nov 2021; status: terminated.
02
Drugs
naxitamab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT04560166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04560166.